UCSF & Collaborators Identify Existing Drugs that Show More Potential Against SARS-CoV-2

UCSF & Collaborators Identify Existing Drugs that Show more Potential against SARS-CoV-2

Scientists at the University of California, San Francisco (UCSF) Quantitative Biosciences Institute (QBI) worked in obscurity for many years delving deeply into how different classes and types of pathogens interact with human proteins, all in the hope of someday finding superior treatments for disease. With the advent of the COVID-19 pandemic, QBI Director Kevan Krogan, PhD, rallied 100 researchers at UCSF and beyond to apply their expertise to the imminent pandemic. Now the QBI Coronavirus Research Group (QCRG), along with a number of prominent collaborators, produced serious results identifying nearly 70 potential drug candidates that could target SARS-CoV-2 as identified by TrialSite News April 2020. A group of authors associated with the collaboration recently published their findings in Nature: they now report they have identified 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials and 28 preclinical compounds). Could this work lead to a direct treatment to COVID-19? What are these compounds?

Preventing the Virus from Multiplying

According to the recent QBI findings, there are 10 drug compounds that co...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee